If you are reading this, you have probably been told that ketamine therapy might be an option for you. You may also be wondering whether it is worth the time, the cost, or the leap.
That hesitation is reasonable. You have likely tried other treatments. You are not looking for a sales pitch. You are looking for a clear answer to whether this is the right next step.
This guide will tell you what a session actually feels like, what the full course of treatment looks like, what it costs, what the risks are, and how it compares to Spravato, TMS, and traditional antidepressants. It will also tell you who this is not for.
By the end, you will know whether ketamine therapy is the right thing to discuss on your next call with your care coordinator.
Before we go deep, here is the short version.
Ketamine therapy at a glance
| What it is | A psychiatric treatment that uses ketamine, an anesthetic medication, at sub-anesthetic doses to produce rapid antidepressant and anti-anxiety effects. |
| FDA status | Ketamine is FDA-approved as an anesthetic. Its use for depression, anxiety, and PTSD is off-label. Spravato (esketamine), a derivative, is FDA-approved for treatment-resistant depression. |
| Modalities offered | IV infusion (most studied), IM injection, intranasal spray, and oral or sublingual lozenges (typically for at-home maintenance after in-clinic induction). |
| Typical course | 6 induction sessions over 2~3 weeks, with maintenance varying by response. |
| Session length | 40~60 minutes of dosing plus 30~60 minutes of recovery for IV. Shorter for IM. |
| Most common side effects | Dissociation (intended), nausea, dizziness, transient blood pressure increase, mild grogginess. |
| Insurance | Largely cash-pay. Some FSA/HSA plans cover it. Spravato is the FDA-approved alternative more often covered by insurance. |
| Driving rule | You cannot drive yourself home after any modality. A ride must be pre-arranged. |
| Best for | Adults with treatment-resistant depression, severe anxiety, PTSD, bipolar depression (with care), or chronic pain comorbid with depression, who have tried two or more conventional treatments without lasting relief. |
That is the headline. The rest of this guide explains each row in plain English.
Key takeaways
- Ketamine has been used safely as an anesthetic for over 50 years, FDA-approved in 1970. Its psychiatric use is off-label but clinically established, with meaningful research support.
- Multiple modalities are commonly offered: IV infusion (most studied), IM injection (faster, shorter), intranasal spray, and oral or sublingual lozenges (typically for at-home maintenance). Each fits a different situation.
- A standard induction is 6 sessions over 2~3 weeks. You will need a ride home after every session, regardless of modality.
- Most insurance plans do not cover ketamine therapy for psychiatric use. A full induction commonly runs $2,500~$5,000 out of pocket. Spravato, the FDA-approved nasal spray version, is more often covered.
- The session involves dissociation. That is intended. Most patients describe it as floating or dreamlike. A clinical team is with you the entire time.
- The bladder and addiction risks you may have read about are tied to recreational, high-dose, frequent use. The therapeutic risk profile is different, though not zero.
- Psycle’s care coordinators can help you figure out whether ketamine, Spravato, or another path makes the most sense for your specific situation and insurance.
What ketamine therapy actually is
Ketamine is an anesthetic medication that has been used in hospitals and emergency rooms for over 50 years. The FDA approved it for anesthesia in 1970.
In the year 2000, researchers at Yale University published the first study showing that a single dose of ketamine improved symptoms in people with depression. Since then, hundreds of clinical trials have investigated its use for psychiatric conditions.
That use, for depression and other psychiatric conditions, is off-label. Off-label prescribing is legal and clinically appropriate, and it is common across medicine. It does mean that most insurance plans will not cover the treatment, since the FDA approval is for anesthesia, not depression.
Conditions with growing evidence for ketamine therapy include:
- Major depressive disorder and treatment-resistant depression
- Suicidal ideation
- Anxiety disorders, including generalized anxiety, social anxiety, and panic disorder
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Substance use disorders, including alcohol and opioid dependence
- Eating disorders, including anorexia nervosa
- Chronic pain conditions, particularly when comorbid with depression
The evidence is strongest for treatment-resistant depression and growing for the rest.
How ketamine works in the brain
Ketamine acts on a different neurotransmitter system than SSRIs. SSRIs act primarily on serotonin. Ketamine acts primarily on glutamate, through a receptor called NMDA. That difference is why it can help when serotonin-based medications have not.
Through its action at NMDA receptors, ketamine produces several downstream effects in the brain:
- Increased activity in the prefrontal cortex, the region responsible for cognition and mood regulation
- Increased neuroplasticity, the brain’s ability to form new neural connections, which may help restructure patterns associated with depression
- Shifts in brainwave patterns, including increases in slow-wave states associated with emotional processing
Researchers are still working out the precise mechanisms behind ketamine’s therapeutic effects. The mechanism is well-supported in broad strokes. The specifics are an active area of research.
Modalities
Psycle works with multiple ketamine modalities. IV infusion is the most studied protocol. IM (intramuscular) injection is faster in both onset and offset. Intranasal spray and oral or sublingual lozenges are typically used for at-home maintenance after an in-clinic induction, under telehealth supervision.
A note on what ketamine therapy is not. It is not Spravato, though it is related. It is not psilocybin or any classical psychedelic. The cultural conversation often blends all three together. They are different.
The molecule in a clinic and the molecule on the street are the same. The dose, setting, and intent are not.
Spravato (esketamine) is an FDA-approved nasal spray derived from one half of the ketamine molecule. Classical psychedelics like psilocybin act on serotonin receptors and remain in clinical trials, not yet FDA-approved.
For more on how Spravato differs from ketamine therapy, see [INTERNAL LINK: “the Psycle Spravato guide” -> Spravato treatment page].
Now, what the actual experience is like.
What a session actually feels like
This is the part most candidates are worried about. So we will walk through it the way it actually happens.
You arrive at the clinic. The clinical team takes your vitals: blood pressure, heart rate, a brief check-in on how you are feeling. This takes about 15 minutes.
You are taken to the treatment room. It is set up to feel calm. A recliner, soft lighting, a blanket. You are offered an eye mask and a curated music playlist. The tone of the room is quiet and focused, not clinical-cold.
If you are doing an IV infusion, a clinician places an IV line in your arm. If you are doing an IM injection, you receive a single injection. If you are using a sublingual lozenge in clinic, you dissolve it under your tongue.
Then the dose begins.
Within five to ten minutes, you start to feel different. Most patients describe it as floating. The boundaries of your body feel softer. Thoughts move more slowly, or arrive from unexpected angles. The music takes on more emotional weight than usual. Some patients describe the experience as dreamlike, occasionally profound, occasionally challenging.
This is dissociation. It is the intended effect. It is also the part that scares people the most before their first session.
The clinical team is in the room or right outside the entire time. They are monitoring your blood pressure and your comfort. If you become anxious during the experience, they can help bring the intensity down.
For an IV infusion, the dosing lasts about 40~60 minutes. For an IM injection, it is shorter. Sublingual lozenges are slower to come on and slower to come off.
After dosing, you rest. The intensity recedes within 30~60 minutes. You drink water. You eat a snack if you want one. Most patients are clear-headed by the time their ride arrives.
You cannot drive yourself home. This is non-negotiable for any modality.
What surprises most people, in a positive direction, is how much agency they retain. You are not unconscious. You are not asleep. You can ask for help, ask for the music to change, or ask for the session to slow down. You are present, just with a different relationship to your usual thoughts.
A typical IV session, minute by minute
- Minutes 0~15. Check-in, vitals, brief conversation with the clinical team.
- Minutes 15~25. Settling into the recliner. IV placement. Eye mask, music, blanket.
- Minutes 25~85. Dosing. The experience itself. The team monitors throughout.
- Minutes 85~145. Come-down and rest. Vitals re-checked. Water, snack, conversation if you want it.
- Minutes 145~155. Discharge to your pre-arranged ride.
How the modalities differ
| IV infusion | IM injection | Intranasal spray | Oral / sublingual | |
|---|---|---|---|---|
| Onset | 5~10 minutes | 5~15 minutes | 10~20 minutes | 20~60 minutes |
| Duration of experience | 40~60 minutes | 30~45 minutes | 30~45 minutes | 60~90 minutes |
| Intensity | Most intense; highly controllable | Moderate to high; less controllable mid-session | Moderate; variable between individuals | Mildest; most variable |
| Where it is administered | In clinic | In clinic | In clinic for induction; at home with telehealth supervision for maintenance | In clinic for induction; at home with telehealth supervision for maintenance |
| Best for | The most studied protocol; first-line clinical option for many candidates | Candidates who want a shorter in-clinic time; situations where IV access is difficult | Candidates who want a less invasive route than IV or IM | At-home maintenance after established response; candidates who are not ready for IV intensity |
Knowing what a single session looks like, the next question is what the full course looks like.
The full course of treatment
A standard induction is 6 sessions over 2~3 weeks. That cadence is intentional. Closer spacing in the first phase has been associated with stronger and more durable response in clinical samples.
After induction, maintenance varies widely. Some patients move to monthly boosters. Others move to as-needed sessions when symptoms return. A smaller group transitions to at-home sublingual maintenance under telehealth supervision. The right cadence is calibrated to your response, not assigned by formula.
There is also a choice of model. Some candidates do medical-model ketamine, which focuses on the neurobiological response and does not require paired therapy. Others do ketamine-assisted psychotherapy, or KAP, where ketamine sessions are paired with prep and integration sessions with a therapist.
The two paths
| Medical-model ketamine | Ketamine-assisted psychotherapy (KAP) | |
|---|---|---|
| Focus | Neurobiological response; symptom relief | Neurobiological response plus structured psychological work |
| Required therapy | No | Yes ~ prep sessions before, integration sessions after |
| Pace | Typically faster to symptom relief | Deeper exploratory work; longer overall arc |
| Total cost | Lower | Higher, due to the added therapy hours |
| Best for | Candidates whose primary goal is symptom relief, or who already have a therapist they work with separately | Candidates who want trauma-focused work, or who want the medication and the psychological work tightly integrated |
The decision between these is one of the most useful things to talk through with your care coordinator. Both are legitimate. Neither is universally better.
A few practical points about the schedule.
You will need a ride home after every session. Plan the rest of the day to be quiet. Most patients describe feeling cognitively slow and a little tired for a few hours after, then back to baseline. Many patients schedule sessions in the late morning or early afternoon, so they have the evening to rest.
What if I miss a session?
Missing a session during induction is not catastrophic, but it does affect the protocol. The course is designed as a sequence, and the spacing matters. If something unavoidable comes up, contact your clinic as early as possible. Rescheduling within the same week is usually preferable to a longer gap.
What if I want to stop?
You can stop at any point. Ketamine does not produce the kind of physical dependence that requires a taper, the way benzodiazepines or opioids do.
Stopping mid-induction means you may not see the full benefit of the protocol. Tell your prescriber so they can update your records and help you think through what comes next. Some patients pause and return later. Others move to a different treatment path entirely.
It is a clinical conversation, not a commitment trap.
The next question, before any of this becomes concrete, is whether you are a candidate.
Who is and is not a candidate
Ketamine therapy is typically considered for adults with:
- Treatment-resistant major depressive disorder
- Severe generalized anxiety
- PTSD
- Bipolar depression (assessed carefully, since bipolar disorder requires specific safeguards)
- OCD
- Chronic pain conditions with comorbid depression
- Substance use disorders (in select cases, with careful screening)
Your specific diagnosis matters less than your full clinical history. The intake process is built to surface that history.
You might be a candidate if
- You have tried two or more antidepressants without lasting relief, or your provider has discussed treatment-resistant depression with you
- You can pay out of pocket, use an FSA or HSA, or are open to discussing financing
- You can arrange a ride home after each session
- You are open to dissociation as part of the treatment
- You do not have uncontrolled high blood pressure, a history of psychosis or schizophrenia, an active substance use disorder, or certain cardiac conditions
If most of those describe your situation, ketamine therapy is worth a structured conversation with a coordinator.
Reasons you may not be a candidate
These are screened during intake, and all of them deserve a conversation with a clinician rather than a self-decision:
- Uncontrolled hypertension. Ketamine raises blood pressure during sessions. If yours is not well-managed, that needs to be addressed first.
- History of psychosis or schizophrenia. Ketamine’s dissociative effects can be destabilizing for people with psychotic disorders.
- Active, untreated substance use disorder. This is assessed case by case rather than as automatic exclusion. Ketamine carries its own misuse potential, which is taken seriously in any responsible clinical setting.
- Pregnancy. Ketamine is not considered safe during pregnancy.
- Certain cardiac conditions. Because ketamine affects heart rate and blood pressure, a cardiac history requires review before treatment begins.
- Active mania in bipolar disorder.
If ketamine therapy is not a fit for you, ask your coordinator about TMS or Spravato. TMS is FDA-cleared for depression and OCD, uses no medication, and is covered by most major insurance plans. Spravato is FDA-approved for treatment-resistant depression and is also covered by most major insurance plans.
A short note on diagnosis. You do not need a formal “treatment-resistant depression” label to be considered. What matters is your treatment history, your current symptoms, and the screening process. Coordinators can help you understand where you fit.
The next question, for almost everyone, is about safety.
What the side effects and risks actually are
Most patients tolerate ketamine therapy well at therapeutic doses on a clinical schedule. That said, side effects are real, and the most responsible thing this guide can do is name them honestly.
Common short-term side effects
According to the National Library of Medicine, the most common side effects during or shortly after sessions include:
- Dissociation. Intended. Intensity varies by dose and by patient. Most patients describe it as floating or dreamlike. Some experience it as challenging.
- Nausea. Common during or immediately after dosing. The clinical team can administer anti-nausea medication.
- Vomiting. Less common, but possible.
- Dizziness or unsteadiness. Most prominent during the come-down. Resolves before discharge.
- Double vision (diplopia). Temporary, while the drug is active.
- Drowsiness. Usually resolves within a few hours.
- Dysphoria. An unpleasant emotional state, possible in a subset of patients.
- Confusion. Difficulty concentrating, typically brief.
- Transient blood pressure and heart rate increase. Monitored throughout the session.
Most of these resolve as the drug clears your system.
Serious side effects worth knowing about
Emergence reactions. A subset of patients experience significant anxiety or distress during a session. In a large observational study, dissociation was reported as a formal adverse event in 14.3% of patients receiving ketamine for psychiatric treatment. Most cases were rated mild. 0.65% were severe. The clinical team is trained to help bring intensity down in real time.
Bladder and urinary tract effects. Documented primarily in chronic, high-dose, recreational use. A 2025 systematic review of 27 clinical studies found urological symptoms in 0% to 24.5% of patients receiving ketamine for psychiatric treatment, with most cases mild or moderate. The wide range reflects how much study populations and protocols vary.
Dependence. Psychological dependence is a real risk with frequent unsupervised use. Clinical maintenance schedules, typically monthly or less, are a fraction of the frequency associated with dependence in recreational contexts. If you have a history of substance use, raise it during intake. It is not an automatic disqualifier, but it shapes the conversation.
Drug interactions
Ketamine should not be combined with certain other medications. Your clinician will review your full medication list during pre-treatment evaluation. The categories to flag include:
- Central nervous system depressants, such as opioids and benzodiazepines
- Sympathomimetic medications, such as some MAO inhibitors
- Theophylline and aminophylline (used in some asthma treatments)
Your prescriber may recommend tapering off certain medications before starting, or may adjust the protocol. Do not stop any medication on your own.
Therapeutic vs recreational use
This is the single most important reframe in any conversation about ketamine. The headlines you have read about ketamine harm almost always reference the right column below, not the left.
| Therapeutic use | Recreational use | |
|---|---|---|
| Setting | Clinical, supervised | Uncontrolled, often unsupervised |
| Dose | Sub-anesthetic, calibrated to weight | Variable, often escalating |
| Frequency | 6 induction sessions over 2~3 weeks, then maintenance as needed | Often multiple times per week, sometimes daily |
| Monitoring | Vitals, screening labs, clinician presence | None |
| Source | Pharmaceutical-grade, prescribed | Unknown purity, often street |
These are different exposures with different risk profiles. The bladder concerns and the addiction concerns reference the second column, not the first. Both columns share a molecule. That is where the similarity ends.
The clinical team monitors your blood pressure during every session, screens for emerging side effects between sessions, and checks in on cravings, mood, and overall response. You are not tracking this alone.
For most candidates, the real decision question is not safety. It is cost.
What it costs and how insurance handles it
Ketamine therapy for psychiatric use is largely cash-pay. Most insurance plans do not cover the medication or the clinic time, since the use is off-label.
The cost ranges, in plain numbers:
- Per IV session: approximately $400~$800
- Per IM session: approximately $300~$600
- Full induction course (6 sessions): approximately $2,500~$5,000
- Maintenance: varies by cadence and modality. Sublingual at-home maintenance is typically the most affordable per month, IV the least.
- KAP add-ons: prep and integration therapy sessions are billed separately
These ranges reflect industry pricing. Your coordinator can give you Psycle’s current pricing directly. Do not make a financial decision on these numbers alone.
A few notes on coverage.
Some FSA and HSA plans cover ketamine therapy as a qualified medical expense. Check your plan documents or call your administrator directly.
Many providers will issue superbills, which you can submit to your insurance for potential out-of-network reimbursement. Reimbursement varies widely by plan and is not guaranteed, but it is worth attempting if your plan includes out-of-network benefits.
Depending on your plan, insurance may also cover adjacent costs even when it does not cover the ketamine itself: your initial psychiatric assessment, talk therapy running alongside treatment, and medical screening.
Spravato, the FDA-approved nasal spray derived from ketamine, is covered by most major insurance plans for treatment-resistant depression. For some candidates, this is the more financially accessible path to a similar mechanism. Whether it fits your situation depends on your diagnosis, your treatment history, and your insurance.
This is exactly the kind of comparison Psycle’s care coordinators are built to walk you through. Before you commit to cash-pay ketamine, it is worth knowing whether Spravato might be covered for your specific situation. The coordinator can run that check for you.
The next question is how ketamine compares to the other options on the table.
How ketamine compares to the other options
Most candidates considering ketamine are also weighing Spravato, TMS, or staying on their current medication. Here is how those compare.
Ketamine vs Spravato
Spravato (esketamine) is a nasal spray derived from ketamine and is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation. Because it is FDA-approved, Spravato must be administered under the Spravato REMS program, which sets specific monitoring and administration requirements.
The comparative evidence on outcomes is mixed. A Cambridge study found that IV ketamine improved depression symptoms more significantly than Spravato in a real-world setting, with a higher rate of remission. Other research, including a study published in JAMA Psychiatry, has found no significant difference in outcomes between the two.
| Ketamine therapy | Spravato (esketamine) | |
|---|---|---|
| FDA status | Off-label for psychiatric use | FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation |
| Insurance coverage | Rarely covered; cash-pay | Covered by most major insurance plans |
| Modality flexibility | IV, IM, intranasal, oral/sublingual | Nasal spray only |
| Dose flexibility | High; can be titrated to response | Lower; standardized dosing regimen |
| Experience intensity | Variable; IV can be deeply dissociative | Typically milder dissociation than IV ketamine |
| Monitoring | Full session monitoring | 2-hour in-clinic observation per dose, per REMS protocol |
| Best for | Candidates who want modality and dose flexibility, who can pay out of pocket, or for whom Spravato has not worked | Candidates who want a covered, FDA-approved option with a standardized protocol |
Ketamine vs TMS vs traditional antidepressants
TMS uses focused magnetic pulses to stimulate the brain regions involved in mood regulation. It is non-invasive, has no systemic side effects, and is FDA-cleared for several conditions including depression and OCD.
Comparative research suggests TMS and ketamine have broadly similar efficacy in treatment-resistant depression, with response rates around 50~60% and remission rates around 30%. Ketamine works faster. TMS takes at least two weeks to begin producing results, and a full course requires more sessions.
| Ketamine | TMS | Traditional antidepressants (SSRIs/SNRIs) | |
|---|---|---|---|
| Speed of onset | Hours to days | 2~4 weeks | 4~8 weeks |
| Time commitment | 6 sessions over 2~3 weeks, plus maintenance | Daily sessions, 5 days a week for 4~6 weeks | Daily medication, ongoing |
| Side effect profile | Dissociation, nausea, dizziness during sessions | Scalp discomfort, mild headache; no systemic side effects | Weight changes, sexual side effects, emotional blunting, fatigue |
| Insurance coverage | Rarely covered | Covered by most major insurance plans | Covered by most insurance plans |
| Durability of effect | Variable; maintenance often needed | Often durable after a full course; some patients return for boosters | Can be durable with continued use |
None of these is universally better. Each fits a different candidate. The choice is rarely about which is “best” and almost always about which trade-offs you can live with.
The myths and worries worth naming
These are the questions candidates ask once they trust the conversation enough to ask them. Each gets a direct answer.
Is clinic ketamine the same as street ketamine?
Same molecule. Different dose, setting, and intent. Clinical ketamine is pharmaceutical-grade, weight-calibrated, administered by a medical team, and given on a defined schedule. Street ketamine is none of those things, and its purity is often unknown. The risks you read about in news coverage almost always reference uncontrolled, frequent, high-dose recreational use, not clinical protocols.
Will I have a bad trip?
The dissociative experience can be challenging at times, especially for first-time patients. The clinical team is present throughout. They are trained to help reduce intensity if needed, and they can adjust dosing in real time. The peak typically lasts about 30 minutes for IV.
Most patients, even those who find early sessions difficult, describe the experience becoming more manageable as treatment progresses.
Is it addictive?
Ketamine has misuse potential, which is why clinical use is supervised. Repeated recreational use can lead to tolerance and withdrawal. Daily or near-daily recreational use is associated with the bladder and dependence risks you may have read about.
Clinical protocols are designed to avoid these patterns. A standard induction is 6 sessions over 2~3 weeks, with widely spaced maintenance after that. The doses are lower, the frequency is far lower, and the setting is supervised. That said, anyone with a history of substance use should disclose it during intake.
Will I lose control?
You will not lose consent. You can ask for the music to change, the pace to slow, or for the clinician’s support at any point. You are not unconscious. You are present, with a different relationship to your usual thoughts.
Is this a psychedelic?
Technically, ketamine is sometimes called an atypical psychedelic because it can produce an altered state of consciousness with some overlapping features. Culturally, “psychedelic” usually refers to classical psychedelics like psilocybin and LSD, which act on serotonin receptors and are not FDA-approved.
Ketamine acts on glutamate, has decades of medical use, and is administered in a clinical setting. It is a different category, even if the cultural shorthand groups them together.
Myth vs reality
| What people fear | What is actually true |
|---|---|
| “It’s a horse tranquilizer.” | It is also a human anesthetic, FDA-approved since 1970, used in hospitals and emergency rooms for over 50 years. |
| “Clinic ketamine is the same as street ketamine.” | Same molecule. Different dose, setting, frequency, and supervision. The risk profiles are not the same. |
| “I’ll lose control during the session.” | You remain conscious and can communicate with the clinical team throughout. |
| “It’s addictive at therapeutic doses.” | Misuse potential exists, which is why use is supervised. Therapeutic protocols are screened, dose-limited, and time-limited. |
| “It’s the same thing as psilocybin.” | Different molecule, different mechanism, different legal status. Ketamine is legally prescribed off-label. Psilocybin remains in clinical trials. |
What the evidence actually shows
Ketamine has been used safely as an anesthetic for over 50 years. The past two decades of psychiatric research have built a credible evidence base for its use in treatment-resistant depression and a growing one for PTSD, bipolar depression, anxiety, and chronic pain.
Treatment-resistant depression
A real-world study published in the Journal of Affective Disorders followed 537 patients with treatment-resistant depression who received ketamine treatment. After an induction course, 53.6% showed a significant reduction in depressive symptoms, and 28.9% achieved full remission.
53.6% ~ Response rate in a real-world study of 537 patients with treatment-resistant depression after a ketamine induction course. Source: Journal of Affective Disorders, 2021
Hours ~ Typical onset of first noticeable change with ketamine, compared to 4~8 weeks for SSRIs.
Multiple randomized controlled trials have found rapid antidepressant effects in patients whose depression had not responded to two or more antidepressants.
Other conditions
- PTSD. A randomized controlled trial in the American Journal of Psychiatry found that repeated ketamine infusions produced significantly greater reduction in PTSD symptom severity compared to an active control, with effects sustained at two weeks post-treatment.
- Chronic pain. A real-world study of 118 chronic pain patients found IV ketamine infusions were associated with a 45% reduction in unplanned pain-related healthcare visits in the six months following treatment.
- Anxiety disorders. A small study published in Psychopharmacology found ketamine produced rapid, dose-dependent reductions in symptoms among patients with treatment-resistant anxiety.
Limits of the current evidence
A few honest caveats worth holding alongside the response data:
- Durability. The antidepressant effect of a single ketamine infusion typically begins to diminish around seven days post-infusion. Long-term durability with maintenance is still being studied.
- Optimal protocol. The ideal number of sessions, dose, maintenance spacing, and role of integration therapy are all active areas of research. Clinics make evidence-informed decisions, but there is no single universal protocol.
- Long-term comparative outcomes. Direct long-term head-to-head trials against Spravato, TMS, or continued antidepressant therapy are still limited.
- Study populations. Treatment-resistant depression is difficult to study cleanly, since patient histories vary widely.
Studies describe averages. Your response is your own.
What integration and follow-up look like
Ketamine therapy is not a one-time event, even when the protocol is short. The integration period, the days and weeks after each session, is where most patients describe the changes consolidating.
Integration is where the work moves from your brain to your life.
Integration means making sense of what comes up during a session and connecting it to your daily life. Ketamine can surface emotions, memories, or shifts in perspective. Integration is the work of turning those shifts into sustainable changes.
Research published in Brain and Behavior suggests ketamine may have stronger and longer-lasting benefits when combined with psychotherapy. The evidence is not absolute, but it is meaningful.
Psycle’s model offers two paths, and the right one depends on what you are looking for.
Medical-model ketamine focuses on the neurobiological response. There is no required paired therapy. You receive the medication, the clinical team monitors your response, and you return for maintenance as needed. Many medical-model patients work with their existing therapist separately.
Ketamine-assisted psychotherapy (KAP) pairs each medication session with prep sessions before and integration sessions after. The therapist helps you set an intention before each session and process what came up after. This path is slower and more expensive, and it tends to work better for candidates who want trauma-focused work or who want the medication and the psychological work tightly integrated.
At-home maintenance with sublingual lozenges, under telehealth supervision, is available for established patients who have completed an in-clinic induction and demonstrated stable response. It is not a starting point. It is a continuation.
Your coordinator can help you figure out which integration path fits you, before you commit to a protocol.
Common objections, named and answered
“I cannot afford it”
This is the most common reason candidates pause. There are real options worth exploring before you decide.
Some FSA and HSA plans cover ketamine as a qualified medical expense. Many providers offer payment plans or superbill reimbursement. And for many candidates, Spravato is covered by insurance and may produce a similar response.
Your coordinator can check your insurance for Spravato and review payment options for ketamine in the same call.
“I have never done a psychedelic and I am scared”
That is reasonable. The clinical setting is built to make the experience as low-stakes as possible. Most first-time patients describe the experience as gentler than they expected. The clinical team is present the entire time, and the dose can be adjusted in real time.
You do not need prior experience with anything to be a candidate.
“I have heard the relief does not last”
Sometimes that is true. Ketamine response often requires maintenance dosing to sustain. Some patients have durable response from an induction course. Others need monthly or as-needed boosters.
Your prescriber will work with you to find the cadence that holds your response. It is rarely a one-and-done.
“What if I have a bad experience?”
Emergence reactions ~ the term for in-session distress ~ happen in a small percentage of sessions. The clinical team is trained to bring intensity down in real time. Anti-anxiety medication can be administered. Doses can be lowered for subsequent sessions.
A difficult session is not the same as a dangerous one.
“I do not want to be the kind of person who needs ketamine to function”
That story is worth examining honestly. Many patients who try ketamine therapy have been on SSRIs for years, with which they had a similar story when they started. Treatment is a tool, not an identity.
The question is whether this tool helps you live the life you want.
“I am worried about my bladder, I read about that”
The bladder concerns documented in the research are tied primarily to chronic, high-dose, recreational use. A 2025 systematic review of 27 clinical studies found urological symptoms in 0% to 24.5% of psychiatric patients, with most cases mild or moderate.
The therapeutic protocol uses lower doses on a much less frequent schedule, which is why the risk profile differs. The clinical team screens for any emerging urinary symptoms during maintenance.
If you have a history of bladder or urinary tract issues, raise it with your coordinator. It is not an automatic disqualifier, but it shapes the conversation.
The next step
If a Psycle coordinator sent you this guide, the next step is small. Reply to them with your questions, or take the consult call they offered. You are not committing to treatment by having one more conversation. You are committing to clarity.
If you found this guide on your own, the next step is the Psycle match questionnaire. A coordinator will follow up to walk you through your options, check your insurance, and help you figure out whether ketamine, Spravato, or another path fits your situation.
You started this guide wondering whether ketamine therapy is the real thing you have been reading about, and whether it is worth what it costs. You now have the framework to answer both questions for yourself, with a coordinator who can fill in the specifics for your situation.
Reply to your coordinator to start your healing journey.
Frequently asked questions
Is ketamine therapy FDA-approved for depression?
Ketamine is FDA-approved as an anesthetic, not as a depression treatment. Its use for depression, anxiety, and PTSD is off-label.
Off-label prescribing is legal and common across medicine. Spravato (esketamine), a derivative of ketamine, is FDA-approved for treatment-resistant depression and is more commonly covered by insurance.
Your care coordinator can help you understand which option fits your situation.
How long does ketamine therapy take to work?
Most patients notice initial changes within hours to a few days after their first session. This is meaningfully faster than SSRIs, which typically take 4~8 weeks.
A standard induction course is 6 sessions over 2~3 weeks. Many patients describe more sustained changes after the full induction rather than after a single session.
Response varies, and durability often depends on maintenance dosing.
Does insurance cover ketamine therapy?
Most insurance plans do not cover ketamine therapy for psychiatric use, since the FDA approval is for anesthesia. Some FSA and HSA plans do cover it.
Many providers issue superbills that you can submit for potential out-of-network reimbursement, though this is not guaranteed.
Spravato, the FDA-approved nasal spray version, is covered by most major insurance plans. Your Psycle coordinator can run that check for you.
Can I drive after a ketamine session?
No. You cannot drive after any modality of ketamine therapy. A pre-arranged ride is required for every session, including sublingual lozenges if dosed in clinic.
Most clinics will not allow you to begin a session without a confirmed ride home. Plan the rest of the day to be quiet, and avoid making important decisions until the next morning.
Is ketamine therapy safe long-term?
Ketamine has been used safely as an anesthetic for over 50 years. The long-term safety profile at therapeutic psychiatric doses, on a typical maintenance schedule, has not shown the bladder or addiction issues documented in recreational use.
The clinical team monitors for emerging side effects between sessions, and most maintenance protocols include periodic check-ins on urinary symptoms, mood, and cravings.
What is the difference between ketamine and Spravato?
Spravato (esketamine) is a derivative of ketamine, made from one half of the ketamine molecule. It is delivered as a nasal spray and is FDA-approved for treatment-resistant depression.
Ketamine therapy in clinics typically uses the full ketamine molecule, delivered via IV, IM, intranasal, or oral/sublingual modalities, and is used off-label.
Spravato is more commonly covered by insurance. Ketamine offers more modality and dose flexibility.
What happens if I want to stop ketamine therapy?
You can stop at any time. There is no withdrawal protocol at therapeutic doses on a clinical schedule.
Tell your prescriber so they can update your records and help you think through what comes next. Some patients pause and return later. Others move to a different treatment path entirely, such as TMS or Spravato, with their coordinator’s help.
Stopping is a clinical conversation, not a commitment trap.
Disclaimer: We know you’ve seen enough misleading health content to last a lifetime. That is why every Psycle Health article is written by experienced copywriters, fact-checked against peer-reviewed research, and medically reviewed by the licensed professional listed at the top of this page. We cite vetted sources and never overstate treatment outcomes. Our content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about your care.
